<DOC>
	<DOCNO>NCT01086306</DOCNO>
	<brief_summary>The purpose study compare incidence hospitalization infection among patient type 2 diabetes mellitus new initiator Saxagliptin new initiator Oral Anti-Diabetic Drug ( OADs ) class DPP4 inhibitor ; compare incidence hospitalization infection associate T-lymphocyte dysfunction ( i.e. , herpes zoster , tuberculosis , non-tuberculous mycobacterial infection [ evaluate composite outcome ] ) among patient type 2 diabetes mellitus new initiator Saxagliptin new initiator OADs class DPP4 inhibitor .</brief_summary>
	<brief_title>Risk Hospitalized Infections Among Patients With Type 2 Diabetes Exposed Oral Antidiabetic Treatment</brief_title>
	<detailed_description>Prospectively design retrospective database study . This study conduct use administrative claim data electronic medical record collect part routine clinical practice</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>18 year age old Newly prescribe Saxagliptin [ OAD class Dipeptidyl peptidase4 ( DPP4 ) inhibitor ] Enrolled respective database least 180 day prior first prescription new OAD Patients identify diagnostic code inpatient diagnostic code infection interest within 180day baseline period Patients DPP4 inhibitor exposure baseline period Patients currently use exenatide insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>